A MASTER PHASE 1/2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BIVALENT BNT162b2 RNA -BASED VACCINE CANDIDATE(S) IN HEALTHY CHILDREN

Project: Research project

Project Details

StatusActive
Effective start/end date2/22/23 → 2/21/28

Funding

  • Pfizer, Inc.: $13,996.00